S&P 500 Energy Sector SEC Filings — March 12, 2026

12-03-2026

Hallador Energy reported strong FY 2025 results with total revenue up 16% YoY to $469.5 million, operating cash flow up 23% YoY to $81.1 million, net income of $41.9 million (vs. $226.1 million loss in FY 2024), and Adjusted EBITDA up 3x to $56.0 million, driven by 19% YoY growth in electric sales and 8% in coal sales. However, Q4 2025 performance weakened with total operating revenue down 30% QoQ to $102.4 million and a net loss of $0.2 million due to power plant availability issues at Merom, while liquidity dipped to $38.8 million from $46.4 million in Q3. The company advanced its ERAS application for a 515 MW gas expansion at Merom (with $14 million deposit) and secured a new $120 million credit facility in March 2026.

• ·Q4 2025 electric sales $71.6 million (down from Q3 $93.2 million).
• ·Q4 2025 coal sales $29.1 million (down from Q3 $51.3 million).
• ·Forward contracted power revenue: $543.47 million through 2029.
• ·New board additions subsequent to year-end: Barbara Sugg and Daniel Hudson.
• ·Conference call scheduled for March 12, 2026 at 5:00 p.m. ET.
• ·ERAS expansion targeted for completion by Q3 2029, representing nearly 50% increase in power generation capabilities from 1 GW base.

12-03-2026

Halozyme Therapeutics, Inc. (NASDAQ: HALO) appointed David Ramsay as Interim Chief Financial Officer effective March 23, 2026, leveraging his prior tenures as CFO from 2003-2009 and 2013-2015, during which the company grew from private to a billion-dollar public biopharmaceutical entity. The company is actively searching for a permanent CFO with a leading executive search firm. Ramsay brings over 30 years of experience in biotech finance, including roles at Bonti, Inc. sold to Allergan plc in October 2018.

• ·Ramsay previously served as SVP and CFO of Bonti, Inc. until its sale to Allergan plc in October 2018.
• ·ENHANZE® licensed to leading partners including Roche, Takeda, Pfizer, Janssen, and others.
• ·Hypercon™ licensed to Janssen, Eli Lilly, and argenx.
• ·Halozyme headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA.

12-03-2026

Devon Energy Corporation (DVN) is acquiring Coterra Energy Inc. (CTRA) through a merger with its wholly-owned subsidiary Cubs Merger Sub, Inc., with Coterra surviving as a direct subsidiary of Devon; the transaction is structured as a tax-free reorganization under Section 368(a) of the Code, though no IRS ruling has been sought. The merger is expected to close in Q2 2026, subject to stockholder approvals, HSR Act clearance, NYSE listing approval, and other conditions, but carries risks including potential failure to meet closing conditions and differing interests of directors/executive officers. No appraisal or dissenters' rights are available to stockholders of either company.

• ·Merger Sub formed January 30, 2026
• ·No entitlement to appraisal or dissenters’ rights under Section 262 of the DGCL
• ·Closing conditions include HSR Act waiting period expiration, SEC effectiveness of S-4 without stop order, and NYSE listing approval for Devon shares
• ·Proxy solicitation by Innisfree M&A for Coterra and MacKenzie Partners for Devon

12-03-2026

Orchestra BioMed Holdings, Inc. reported total revenue of $33,482 for the year ended December 31, 2025, surging 1,169% YoY from $2,638, driven by partnership revenue jumping to $32,871 (+1,539%), though product revenue declined 3% to $611. Net loss narrowed 14% to $52,701 from $61,024, with operating loss improving 19% to $51,807, but R&D expenses rose 36% to $58,185 and total expenses increased 27% to $85,289. The company expects up to $21.0M in proceeds from Haemonetics' acquisition of Vivasure, its 10.9% investee, including $4.7M upfront received in January 2026.

• ·Net cash used in operating activities improved slightly to $48,963 in 2025 from $50,558 in 2024.
• ·Net cash from investing activities was ($26,941) in 2025 vs $13,089 provided in 2024.
• ·Vivasure acquisition by Haemonetics closed January 9, 2026; remainder of $21.0M proceeds tied to future earnouts beyond one year.
• ·Filing date: March 12, 2026.

12-03-2026

IIOT-OXYS, Inc. entered into a Securities Purchase Agreement on March 6, 2026, with GHS Investments, LLC (owned by three of the Company's four directors) for up to 97 shares of Series D Convertible Preferred Stock at $1,000 per share, totaling up to $88,000, with an initial closing of 47 shares ($43,000 purchase + 4 incentive shares) completed on March 12, 2026. The deal includes participation rights, most favored nation status, and a $1,760 finder's fee to J.H. Darbie & Co., Inc., but involves related-party risks and potential dilution from reserving 150,000,000 common shares. An additional closing of up to 50 shares ($45,000 + 5 incentive) is at GHS's discretion upon filing the 2025 Form 10-K.

• ·Company must maintain 2x common stock coverage for GHS-held Preferred Stock.
• ·30-day grace period for filing 2025 Form 10-K as non-default event.
• ·Issuance exempt under Section 4(a)(2) and Rule 506(b) of Securities Act.